Table 3.

Relative survival percent, 95% confidence intervals and survival difference between year 1 and 5 for hematopoietic malignancy patients aged 0–89 years in Sweden 1 and 5 years after diagnosis.

Hematopoietic neoplasm survival (%)
Period		1-year	5-year		1–5 years%a
Men
1967–1971	50	[49; 51]*	26	[24; 27] *	24
1972–1976	57	[56; 58]	29	[28; 31]	28
1977–1981	63	[62; 64]*	35	[34; 36]*	28
1982–1986	68	[67; 69]*	40	[39; 41]*	28
1987–1991	71	[70; 72]*	43	[42; 45]*	28
1992–1996	75	[74; 76]	48	[47; 50]*	27
1997–2001	77	[76; 78]*	52	[51; 53]*	25
2002–2006	81	[80; 82]*	59	[58; 60]*	22
2007–2011	84	[83; 85]	64	[63; 65]*	20
2012–2016	86	[85; 86]	66	[65; 67]	20
Women
1967–1971	52	[50; 53]*	28	[27; 30]*	24
1972–1976	59	[58; 60]*	33	[32; 35]*	26
1977–1981	65	[64; 66]*	38	[36; 39]*	28
1982–1986	70	[69; 71]*	43	[42; 45]*	27
1987–1991	74	[73; 75]*	48	[46; 49]*	26
1992–1996	77	[76; 78]*	53	[51; 54]*	24
1997–2001	79	[79; 80]*	57	[55; 58]*	22
2002–2006	81	[81; 82]*	62	[61; 63]*	19
2007–2011	86	[85; 86]*	67	[66; 69]*	19
2012–2016	86	[86; 87]	69	[68; 70]	17

^a 1–5 years% is the difference between survival percentages of year 1 and 5.

*Indicates that the 95%CIs between periodic survival percentages do not overlap, compared to the period below.